Table of Contents

2019-2024 Global Hyperimmune Globulins Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Hyperimmune Globulins Consumption 2014-2024
  • 2.1.2 Hyperimmune Globulins Consumption CAGR by Region
• 2.2 Hyperimmune Globulins Segment by Type
  • 2.2.1 Hepatitis B Immunoglobulins
  • 2.2.2 Rabies Immunoglobulins
  • 2.2.3 Tetanus Immunoglobulins
  • 2.2.4 Rho(D) Immunoglobulins
  • 2.2.5 Others
• 2.3 Hyperimmune Globulins Consumption by Type
  • 2.3.1 Global Hyperimmune Globulins Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Hyperimmune Globulins Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Hyperimmune Globulins Sale Price by Type (2014-2019)
• 2.4 Hyperimmune Globulins Segment by Application
  • 2.4.1 Government Institutions
  • 2.4.2 Private Sector
  • 2.4.3 Other
• 2.5 Hyperimmune Globulins Consumption by Application
  • 2.5.1 Global Hyperimmune Globulins Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Hyperimmune Globulins Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Hyperimmune Globulins Sale Price by Application (2014-2019)

3 Global Hyperimmune Globulins by Players

• 3.1 Global Hyperimmune Globulins Sales Market Share by Players
  • 3.1.1 Global Hyperimmune Globulins Sales by Players (2017-2019)
  • 3.1.2 Global Hyperimmune Globulins Sales Market Share by Players (2017-2019)
• 3.2 Global Hyperimmune Globulins Revenue Market Share by Players
  • 3.2.1 Global Hyperimmune Globulins Revenue by Players (2017-2019)
  • 3.2.2 Global Hyperimmune Globulins Revenue Market Share by Players (2017-2019)
• 3.3 Global Hyperimmune Globulins Sale Price by Players
• 3.4 Global Hyperimmune Globulins Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Hyperimmune Globulins Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Hyperimmune Globulins Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Hyperimmune Globulins by Regions

• 4.1 Hyperimmune Globulins by Regions
  • 4.1.1 Global Hyperimmune Globulins Consumption by Regions
  • 4.1.2 Global Hyperimmune Globulins Value by Regions
• 4.2 Americas Hyperimmune Globulins Consumption Growth
• 4.3 APAC Hyperimmune Globulins Consumption Growth
• 4.4 Europe Hyperimmune Globulins Consumption Growth
• 4.5 Middle East & Africa Hyperimmune Globulins Consumption Growth

5 Americas

• 5.1 Americas Hyperimmune Globulins Consumption by Countries
  • 5.1.1 Americas Hyperimmune Globulins Consumption by Countries (2014-2019)
  • 5.1.2 Americas Hyperimmune Globulins Value by Countries (2014-2019)
• 5.2 Americas Hyperimmune Globulins Consumption by Type
• 5.3 Americas Hyperimmune Globulins Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Hyperimmune Globulins Consumption by Countries
  • 6.1.1 APAC Hyperimmune Globulins Consumption by Countries (2014-2019)
  • 6.1.2 APAC Hyperimmune Globulins Value by Countries (2014-2019)
• 6.2 APAC Hyperimmune Globulins Consumption by Type
• 6.3 APAC Hyperimmune Globulins Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Hyperimmune Globulins by Countries
  • 7.1.1 Europe Hyperimmune Globulins Consumption by Countries (2014-2019)
  • 7.1.2 Europe Hyperimmune Globulins Value by Countries (2014-2019)
• 7.2 Europe Hyperimmune Globulins Consumption by Type
• 7.3 Europe Hyperimmune Globulins Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Hyperimmune Globulins by Countries
  • 8.1.1 Middle East & Africa Hyperimmune Globulins Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Hyperimmune Globulins Value by Countries (2014-2019)
• 8.2 Middle East & Africa Hyperimmune Globulins Consumption by Type
• 8.3 Middle East & Africa Hyperimmune Globulins Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.2 Hyperimmune Globulins Distributors
• 10.3 Hyperimmune Globulins Customer

11 Global Hyperimmune Globulins Market Forecast

• 11.1 Global Hyperimmune Globulins Consumption Forecast (2019-2024)
• 11.2 Global Hyperimmune Globulins Forecast by Regions
  • 11.2.1 Global Hyperimmune Globulins Forecast by Regions (2019-2024)
  • 11.2.2 Global Hyperimmune Globulins Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Hyperimmune Globulins Forecast by Type
• 11.8 Global Hyperimmune Globulins Forecast by Application

12 Key Players Analysis

• 12.1 CSL Behring
  • 12.1.1 Company Details
  • 12.1.2 Hyperimmune Globulins Product Offered
  • 12.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 CSL Behring News
• 12.2 Grifols
  • 12.2.1 Company Details
  • 12.2.2 Hyperimmune Globulins Product Offered
  • 12.2.3 Grifols Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Grifols News
• 12.3 Biotest
  • 12.3.1 Company Details
  • 12.3.2 Hyperimmune Globulins Product Offered
  • 12.3.3 Biotest Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Biotest News
• 12.4 Kedrion
  • 12.4.1 Company Details
  • 12.4.2 Hyperimmune Globulins Product Offered
  • 12.4.3 Kedrion Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Kedrion News
• 12.5 CBPO
  • 12.5.1 Company Details
  • 12.5.2 Hyperimmune Globulins Product Offered
  • 12.5.3 CBPO Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 CBPO News
• 12.6 Emergent (Cangene)
  • 12.6.1 Company Details
  • 12.6.2 Hyperimmune Globulins Product Offered
  • 12.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Emergent (Cangene) News
• 12.7 Kamada
  • 12.7.1 Company Details
  • 12.7.2 Hyperimmune Globulins Product Offered
  • 12.7.3 Kamada Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Kamada News
• 12.8 CNBG
  • 12.8.1 Company Details
  • 12.8.2 Hyperimmune Globulins Product Offered
  • 12.8.3 CNBG Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 CNBG News
• 12.9 Hualan Bio
  • 12.9.1 Company Details
  • 12.9.2 Hyperimmune Globulins Product Offered
  • 12.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.9.4 Main Business Overview
  • 12.9.5 Hualan Bio News
• 12.10 Shanghai RAAS
  • 12.10.1 Company Details
  • 12.10.2 Hyperimmune Globulins Product Offered
  • 12.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.10.4 Main Business Overview
  • 12.10.5 Shanghai RAAS News
• 12.11 Sichuan Yuanda Shuyang
• 12.12 ADMA Biologics

13 Research Findings and Conclusion

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

According to this study, over the next five years the Hyperimmune Globulins market will register a 11.6% CAGR in terms of revenue, the global market size will reach US$ 140 million by 2024, from US$ 82 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Hyperimmune Globulins business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Hyperimmune Globulins market by product type, application, key manufacturers and key regions and countries.

This study considers the Hyperimmune Globulins value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Government Institutions
Private Sector
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Hyperimmune Globulins consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Hyperimmune Globulins market by identifying its various subsegments.
Focuses on the key global Hyperimmune Globulins manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Hyperimmune Globulins with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Hyperimmune Globulins submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.